Patent intelligence · EP
EP 3027208
DIAGNOSE UND THERAPIE VON KREBS MIT KREBSSTAMMZELLEN
DIAGNOSE UND THERAPIE VON KREBS MIT KREBSSTAMMZELLEN
Patent details — EP 3027208
- Jurisdiction
- EP
- Status
- granted
- Grant date
- Jun 8, 2016
- Expiration
- Jun 3, 2036
- Applicant
- BIONTECH AG [DE]
- CPC classes
- A61K 39/ 395 A I, A61K 47/ 48 A I, A61K/476851
Quick answer
EP 3027208 (DIAGNOSE UND THERAPIE VON KREBS MIT KREBSSTAMMZELLEN) is held by BIONTECH AG [DE]. Status: granted. Granted Jun 8, 2016. Expires Jun 3, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIONTECH AG [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 39/ 395 A I, A61K 47/ 48 A I, A61K/476851
More from BIONTECH AG [DE]
Related pharmaceutical patents in our USPTO index.
-
AU 2022206771
Drug conjugates comprising antibodies against Claudin 18.2
granted -
EP 3791896
KOMBINATIONSTHERAPIE MIT ANTIKÖRPERN GEGEN CLAUDIN 18.2 ZUR BEHANDLUNG VON KREBS
granted -
LT 3254695
COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
granted -
EP 3708579
CLAUDIN-6-SPEZIFISCHE IMMUNREZPTOREN UND T-ZELL-EPITOPE
granted -
HR P20200591
ANTIBODIES SPECIFIC FOR CLAUDIN 6 (CLDN6)
granted -
US 2020199221
ANTIBODIES USEFUL IN CANCER DIAGNOSIS
granted -
WO 2020095183
COMBINAISON POUR LE TRAITEMENT DU CANCER
granted -
US 2019076525
THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
granted
Frequently asked questions
What is US patent 3027208?
EP 3027208 (DIAGNOSE UND THERAPIE VON KREBS MIT KREBSSTAMMZELLEN) is held by BIONTECH AG [DE]. Status: granted. Granted Jun 8, 2016. Expires Jun 3, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Who owns EP 3027208?
BIONTECH AG [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does EP 3027208 expire?
Our index shows an expiration date of Jun 3, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.